Current concepts in the pathogenesis of Alzheimer's disease

American Journal of Medicine

Volumn 103, Issue 3 A, 1997, Pages 3S-10S

  Carr, D B ^a   Goate, A ^a   Phil, D ^c   Morris, J C ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; HEAVY METAL; OXYGEN RADICAL; TACRINE;

AGING; ALZHEIMER DISEASE; CHROMOSOME 19; CONFERENCE PAPER; GENE MUTATION; HUMAN; NEUROFIBRILLARY TANGLE; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SENILE PLAQUE;

EID: 0030818058     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00262-3     Document Type: Conference Paper

References (89)

1. Evans DA. Descriptive epidemiology of Alzhemier's disease. Khachaturian ZS, Radebaugh TS. Alzheimer's Disease. 1996;CRC Press, Boca Raton, Florida.
2. Max W. The economic impact of Alzheimer's disease. Neurology. 43:(suppl 4):1993;S6-S10.
3. Ernst RL, Hay JW. The US Economic and Social Costs of Alzheimer's Disease Revisited. Am J Public Health. 84:1994;1261-1264.
4. Evans DA, Funkenstein H, Albert MS. Prevalence of Alzheimer's disease in a community population of older persons. JAMA. 262:1989;2551-2556.
5. Bachman DL, Wolf PA, Linn RT, et al. Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study. Neurology. 43:1993;515-519.
6. Von Dras DD, Blumenthal HT. Dementia of the aged: disease or atypical accelerated aging? Biopathological and psychological perspectives. JAGS. 40:1992;285-294.
7. Breitner JCS, Welsh KA. Genes and recent developments in the epidemiology of Alzheimer's disease and related dementia. Epidemiol Rev. 17:1995;39-47.
8. Blass JP. Pathophysiology of the Alzheimer's syndrome. Neurology. 43:1993;S25-S38.
9. Craik FIM. Memory function in normal aging. Yanagihara T, Petersen RC. Memory Disorders, Research and Clinical Practice. 1991;347-367 Marcel Dekker, New York.
10. Rubin EH, Storandt M, Miller JP, et al. Influence of age on clinical and psychometric assessment of subjects with very mild or mild dementia of the Alzheimer type. Arch. Neurol. 50:1993;380-383.
11. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Association, Washington, DC.
12. Morris JC. Relationship of plaques and tangles to Alzheimer's disease phenotype. Goate AM, Ashall F. The Pathobiology of Alzheimer's Disease. 1995;194 Academic Press, San Diego.
13. O'Connor DW, Pollitt PA, Hyde JB, et al. Do general practitioners miss dementia in elderly patients? Br Med J. 297:1988;1107-1110.
14. Seltzer B, Sherwin I. A comparison of clinical features in early and late onset primary degenerative dementia. Arch Neurol. 40:1984;143-146.
15. Siu AL. Screening for dementia and investigating its causes. Ann Intern Med. 115:1991;122-132.
16. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter for diagnosis and evaluation of dementia. Neurology. 44:1994;2203-2206.
17. Crystal HA, Dickson DW, Sliwinski MJ, et al. Pathological markers associated with normal aging and dementia in the elderly. Ann Neurol. 34:1993;566-573.
18. Hubbard B, Anderson J. Sex differences in age-related brain atrophy. Lancet. i:1983;14447-14448.
19. Murphy DBM, DeCarli CF, McIntosh AR, et al. Sex differences in human brain morphometry and metabolism: an in vivo quantitative magnetic resonance imaging and positron emission tomography study on the effect of aging. Arch Gen Psych. 53:1996;585-920.
20. Takeda S, Matsuzawa T. Age-related brain atrophy: a study with computed tomography. J Gerontol. 40:1985;159-163.
21. Ulrich J. Alzheimer changes in nondemented patients younger than sixty-five: possible early stages of Alzheimer's disease and senile dementia of Alzheimer type. Ann Neurol. 17:1985;273-277.
22. Price JL. The relationship between tangle and plaque formation during healthy aging and mild dementia. Neurobiol Aging. 14:1993;661-663.
23. Giannakopoulos P, Hof PR, Surini M, et al. Quantitative immunohistochemical analysis of the distribution of nerve fibrillary tangels and senile plaques in the cerebral cortex of nonagenarians and centenarians. Acta Neuropathol. 85:1993;602-610.
24. Hyman BT. Neuronal system disruption in Alzheimer disease. Dementia update. Paper presented at the American Academy of Neurology, May 6-13, 1995, Seattle, WA.
25. Terry RD, Hansen LA, DeTeresa R, et al. Senile dementia of the Alzheimer type without neocortical neurofibrillary tangles. J Neuropathol Exp. Neurol. 46:1987;262-268.
26. Morris JC, McKeel DW, Storandt M, et al. Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology. 41:1991;469-478.
27. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol. 42:1985;1097-1105.
28. Morris JC, Storandt M, McKeel DW, et al. Cerebral amyloid deposition and diffuse plaques in "normal" aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology. 46:1996;707-719.
29. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 30:1991;572-580.
30. Gomez-Isla T, Price JL, McKeel DW, et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 16:1996;4491-4500.
31. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand. 76:1987;465-479.
32. Canadian Study of Health and Aging; study methods and prevalence of dementia. Can Med Assoc J. 150:1994;899-913.
33. Graves AB, Kukull WA. Morris JC. Handbook of Dementing Illnesses. 1994;23-69 Marcel Dekker, New York.
34. The Canadian Study of Health and Aging. Risk factors for Alzheimer's disease in Canada. Neurology. 44:1994;2073-2080.
35. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high avidity binding to beta-amyloid and increased frequency of type 4 allele in late onset Alzheimer's disease. Proc Natl Acad Sci USA. 90:1993;1977-1981.
36. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer disease in late onset families. Science. 261:1993;921-923.
37. Mann DMA, Yuonis N, Jones D, Stoddart RW. The time course of pathological events in Down's syndrome with particular reference to the involvement in microglial cells and deposits of B/A4. Neurodegeneration. 1:1992;201-215.
38. Bachman DL, Wolf PA, Linn R, et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology. 42:1992;115-119.
39. Rocca WA, Bonaiuto S, Lippi A, et al. Prevalence of clinically diagnosed Alzheimer's disease and other dementing disorders: a door to door survey in Appignano, Macerata Province, Italy. Neurology. 40:1990;626-631.
40. Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol. 51:1994;896-900.
41. Filit H, Weinreb H, Cholst I, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia - Alzheimer's type. Psychoneuroendocrinology. 11:1986;337-345.
42. Nee LE, Eldridge R, Sunderland T, et al. Dementia of the Alzheimer type: clinical and family study of 22 twin pairs. Neurology. 37:1987;359-363.
43. Breitner JCS, Welsh KA, Gau BA, et al. Alzheimer's disease in the National Academy of Sciences-National Research Council Registry of aging twin veterans. III. Detection of cases, longitudinal results, and observations on twin concordance. Arch Neurol. 52:1995;763-771.
44. Stern Y, Gurland B, Tatemichi TK, Tang MX, et al. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA. 271:1994;1004-1010.
45. Snowdon DA, Kemper SJ, Mortimer JA, et al. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. JAMA. 275:1996;528-532.
46. Swaab DF. Brain aging and Alzheimer's disease, "wear and tear" versus "use it or lose it" Neurobiol Aging. 12:1991;317-324.
47. van Duijn CM, Tanja TA, Haaxma R, et al. Head trauma and the risk of Alzheimer's disease. Am J Epidemiol. 135:1992;775-782.
48. Roberts GW, Gentleman SM, Lynch A, et al. Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psych. 57:1994;419-425.
49. Roberts GW, Allsop D, Bruton C. The occult aftermath of boxing. J Neurol Neurosurg Psych. 53:1990;373-378.
50. Aronson MK, Ooi WL, Morgenstern H, et al. Cortical senile plaques in coronary artery disease, aging, and Alzheimer's disease. Neurobiol Aging. 11:1990;601-607.
51. Ferrucci L, Guralnik JM, Salive ME, et al. Cognitive impairment and risk of stroke in the older population. JAGS. 44:1996;237-241.
52. Skoog I, Nilsson L, Palmertz B, et al. A population-based study of dementia in 85 year olds. N Engl J Med. 328:1993;153-158.
53. Schellenberg GD. Genetic dissection of Alzheimer disease, a heterogeneous disorder. Proc Natl Acad Sci. 92:1995;8552-8559.
54. Oliver C, Holland AJ. Down's syndrome and Alzheimer's disease: a review. Psychol Med. 16:1986;307-322.
55. Edland SD, Silverman JM, Peskind ER, et al. Increased risk of dementia in mothers of Alzheimer's disease cases: Evidence for maternal inheritance. Neurology. 47:1996;254-256.
56. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 349:1991;704-706.
57. Lendon CL, Ashall F, Goate A. Exploring the etiology of Alzheimer's disease using molecular genetics. JAMA. 277:1997;825-831.
58. Hendriks L, Van Duijn CM, Cras P, et al. Pre-senile dementia and cerebral haemmorhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat. Genet. 1:1992;218-221.
59. Pericek-Vance M, Foncin JF, Montesi M, et al. Genetic evidence for a novel familial Alzheimer's locus on chromosome 14. Nature Genet. 2:1992;330-334.
60. Van Broeckhoven C, Backhovens H, Cruts M. Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3. Nature Genet. 2:1992;335-339.
61. Van Broeckhaven C. Pre-senilers and Alzheimer's disease. Nature Genet. 11:1995;230-232.
62. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 APP mutations linked to familial Alzheimer's disease. Nat Med. 2:1996;864-870.
63. Roses AD. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol. 53:1994;429-437.
64. Manba Y, Tomonaga M, Kawasaki H, et al. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer and kuru plaque amyloid in Creutzfel-Jakob disease. Brain Res. 541:1991;163-166.
65. Strittmatter WJ, Weisgraber KH, Goedert M, et al. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain as a function of apolipoprotein E genotype. Exp Neurol. 125:1994;163-171.
66. Boyles JK, Zoellner CD, Anderson LJ, et al. A role for apolipoprotein E, apolipoprotein A-1, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest. 83:1989;1015-1031.
67. Gale CR, Martyn CN, Cooper C. Cognitive impairment and mortality in a cohort of elderly people. Br Med J. 312:1996;608-611.
68. Jeandel C, Nicolas MB, Dubois F, et al. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology. 35:1989;275-282.
69. Sano M, Ernesto C, Thomas R, et al. A Controlled Trial of Selegiline, Alpha-Tocopherol, or both as Treatment for Alzheimer's Disease. N Engl J Med. 336:1997;1216-1222.
70. Cotton P. Constellation of risks and processes seen in search for Alzheimer's clues. JAMA. 271:1994;89-91.
71. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science. 275:1997;630-631.
72. Breitner JCS, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: intial results of a co-twin control study. Neurology. 44:1994;227-232.
73. Rogers J, Kirby LC, Hempleman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
74. Mattson MP, Cheng B, Davis D, et al. Beta amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 12:1992;379-389.
75. Masliah E, Mallory M, Deerinck T, et al. Re-evaluation of the structural organization of neuritic plaques in Alzheimer's disease. J Neuropathol Exp Neurol. 52:1993;619-632.
76. Blass JP. Pathophysiology of the Alzheimer's syndrome. Neurology. 43:1993;S25-S38.
77. Thase ME, Tigner R, Smelzer DJ, et al. Age-related neuropsychological deficits in Down's syndrome. Biol Psychiatry. 19:1984;571-585.
78. Yankner BA, Dawes LR, Fischer S, et al. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science. 245:1989;417-420.
79. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 373:1995;523-527.
80. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, abeta elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
81. Storey E, Masters CL. Amyloid, aluminum, and the aetiology of Alzheimer's disease. Med J Austral. 163:1995;256-259.
82. Rensburg SJ, Carstens ME, Potocnik FCV, et al. Transferrin C2 and Alzheimer's disease: another piece of the puzzle found? Med Hypoth. 44:1995;268-272.
83. Itzhaki RF. Possible factors in the etiology of Alzheimer's disease. Molec Neurobiol. 9:1994;1-13.
84. Swaab DF, Raadsheer FC, Endert E, et al. Increased cortisol levels in aging and Alzheimer's disease in postmortem cerebrospinal fluid. J Neuroendocrinol. 6:1994;681-687.
85. O'Brien JT, Schweitzer I, Ames D, et al. The function of the hypothalmic-pituitary-adrenal axis in Alzheimer's disease. Response to insulin hypoglycemia. Br J Psych. 165:1994;650-657.
86. Aisen PS, Davis KL. The search for disease-modifying treatment for Alzheimer's disease. Neurology. 48:(suppl 6):1997;S35-S41.
87. Stern RG, Davis KL. Treatment approaches in Alzheimer's disease: past, present, and future. Weiner MF. The Dementias: Diagnosis and Management. 1991;227-248 American Psychiatric Press, Washington, DC.
88. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 271:1994;985-991.
89. Poirier J, Aubert I, Quirion R, et al. Apolipoprotein E4 and cholinergic activity in Alzheimer's disease. Becker R, Giacobini. Alzheimer Disease: From Molecular Biology to Therapy. 1996;55-60 Birkhauser, Boston.